Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1681
http://purl.obolibrary.org/obo/NCIT_C1681
|
|---|---|
| Preferred Name | Alemtuzumab |
| Definitions |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04) |
|---|---|
| prefLabel | Alemtuzumab
|
| label | Alemtuzumab
|
| PDQ_Closed_Trial_Search_ID | 37783
|
| code | C1681
|
| Has_Target | |
| prefixIRI | NCIT:C1681
|
| in_subset |
See more
See less
|
| Display_Name | Alemtuzumab
|
| Preferred_Name | Alemtuzumab
|
| FDA_UNII_Code | 3A189DH42V
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Alemtuzumab
|
| CAS_Registry | 216503-57-0
|
| NSC Number | 715969
|
| NCI_Drug_Dictionary_ID | 37783
|
| Legacy Concept Name | Alemtuzumab
|
| type | |
| ALT_DEFINITION | A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 37783
|
| Accepted_Therapeutic_Use_For | Chronic Lymphocytic Leukemia (CLL)
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C0383429
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |